LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the major malignancies and the second most common cause of cancer-related death worldwide. Sorafenib, an approved first-line systematic treatment agent for HCC, is capable to effectively improve the survival of patients with advanced HCC. The long...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuan, Chen, Lamei, Yuan, Huabing, Guo, Shenghong, Wu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008197/
https://www.ncbi.nlm.nih.gov/pubmed/32103983
http://dx.doi.org/10.2147/OTT.S229957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008197/
https://www.ncbi.nlm.nih.gov/pubmed/32103983
http://dx.doi.org/10.2147/OTT.S229957

Ejemplares similares